Aicuris announced today the appointment of Jacques Dumas, Ph.D., as Chief Scientific Officer (CSO), effective January 1, 2025. Dr. Dumas brings over 30 years of experience in pharmaceutical research and development (R&D), with a strong track record of advancing innovative medicines in oncology and infectious diseases from the discovery to launch.

Aicuris has initiated its Phase 1 trial to evaluate the safety, tolerability and pharmacokinetics of AIC468, an antiviral ASO, in healthy volunteers.

Aicuris has appointed Dr. Cynthia Wat, a highly accomplished pharmaceutical physician with over 25 years of experience, as Chief Medical Officer. Dr. Wat will lead the management and global development of Aicuris’ clinical pipeline of innovative therapeutic candidates.

Aicuris reached major milestones in 1H 2024 for letermovir (marketed by MSD as PREVYMIS®), pritelivir, and AIC468 highlighting the rapid progress in developing anti-viral solutions for immunocompromised patients.

The cooperation provides us with the opportunity to combine exceptional German antiviral research with our development capabilities and clinical expertise to develop novel therapies for immunocompromised patients.